Victory Capital Management Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 74.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 280,370 shares of the biopharmaceutical company’s stock after purchasing an additional 119,567 shares during the period. Victory Capital Management Inc.’s holdings in Gilead Sciences were worth $19,844,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Seizert Capital Partners LLC grew its holdings in shares of Gilead Sciences by 4.6% in the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after acquiring an additional 27,547 shares in the last quarter. Investment Centers of America Inc. grew its holdings in shares of Gilead Sciences by 7.2% in the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after acquiring an additional 1,958 shares in the last quarter. Capital Asset Advisory Services LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $875,000. First PREMIER Bank lifted its stake in Gilead Sciences by 9.0% in the 2nd quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock valued at $1,524,000 after purchasing an additional 1,787 shares during the last quarter. Finally, Karp Capital Management Corp acquired a new stake in Gilead Sciences in the 1st quarter valued at about $37,520,000. Institutional investors own 74.38% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) traded up $0.75 during trading hours on Friday, hitting $73.77. 7,698,200 shares of the stock were exchanged, compared to its average volume of 9,360,261. The firm has a market capitalization of $95,383.76, a price-to-earnings ratio of 7.62, a PEG ratio of -1.22 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 4.74 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.75 earnings per share. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.82%. Gilead Sciences’s payout ratio is 23.69%.
Several equities research analysts recently issued reports on GILD shares. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Thursday, August 31st. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price for the company in a research note on Friday, October 13th. Credit Suisse Group reiterated an “outperform” rating and issued a $85.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $85.92.
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/11/gilead-sciences-inc-gild-holdings-boosted-by-victory-capital-management-inc.html.
In related news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the completion of the transaction, the executive vice president now owns 113,237 shares in the company, valued at approximately $8,945,723. The disclosure for this sale can be found here. In the last 90 days, insiders sold 446,819 shares of company stock worth $36,269,486. 1.30% of the stock is owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.